APA (7th ed.) Citation

Dzienis, M., Mojebi, A., Keeping, S., Black, C. M., Giezek, H., Naicker, N., . . . Zheng, D. (2025). Pembrolizumab with Carboplatin and Paclitaxel Versus Alternative Systemic Treatments Recommended for the First-Line Treatment of Recurrent/Metastatic Head and Neck Cancer. Advances in Therapy, 42(6), 2690-2707. https://doi.org/10.1007/s12325-025-03144-4

Chicago Style (17th ed.) Citation

Dzienis, Marcin, et al. "Pembrolizumab with Carboplatin and Paclitaxel Versus Alternative Systemic Treatments Recommended for the First-Line Treatment of Recurrent/Metastatic Head and Neck Cancer." Advances in Therapy 42, no. 6 (2025): 2690-2707. https://doi.org/10.1007/s12325-025-03144-4.

MLA (9th ed.) Citation

Dzienis, Marcin, et al. "Pembrolizumab with Carboplatin and Paclitaxel Versus Alternative Systemic Treatments Recommended for the First-Line Treatment of Recurrent/Metastatic Head and Neck Cancer." Advances in Therapy, vol. 42, no. 6, 2025, pp. 2690-2707, https://doi.org/10.1007/s12325-025-03144-4.